TY - JOUR T1 - Incidence and Prognostic Implications of Diplopia in Patients with Giant Cell Arteritis JF - The Journal of Rheumatology JO - J Rheumatol SP - 1562 LP - 1564 DO - 10.3899/jrheum.130983 VL - 41 IS - 7 AU - MORITZ HAERING AU - ANDREAS HOLBRO AU - MARGARITA G. TODOROVA AU - MARKUS ASCHWANDEN AU - FRIEDERIKE KESTEN AU - CHRISTOPH T. BERGER AU - ALAN TYNDALL AU - DANIELA BENZ AU - CHRISTOPH HESS AU - THOMAS DAIKELER Y1 - 2014/07/01 UR - http://www.jrheum.org/content/41/7/1562.abstract N2 - To the Editor:Giant cell arteritis (GCA) is the most common systemic vasculitis, with an incidence increasing with advanced age1. Patients present with a systemic inflammatory syndrome with constitutional symptoms and/or with ischemic events resulting from vascular occlusion including temporary or permanent visual loss1,2,3,4. Another less-recognized ophthalmologic manifestation of GCA is diplopia. Previous studies reported diplopia to occur among 6–20% of patients with ophthalmic symptoms and in 3–8% of unselected patients with GCA5,6,7. Diplopia, along with jaw claudication, is a symptom that correlates with a positive biopsy finding8. Diplopia might be temporary and thus might be missed.We prospectively analyzed incidence, clinical presentation, and outcome of patients with diplopia at diagnosis within our prospective single-center GCA cohort (Basler Riesenzellarteriitis Kohorte: BARK). The center’s institutional review board approved our study. Briefly, patients presenting at the University Hospital Basel with newly diagnosed GCA according to American College of Rheumatology criteria9 were included after having given informed consent. Demographic, clinical, laboratory, and radiologic (including vascular ultrasound10) data of all patients were recorded at … Address correspondence to Dr. T. Daikeler, Division of Rheumatology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland. E-mail: thomas.daikeler{at}usb.ch ER -